Background
==========

HEP3002 is an ongoing, open-label, early access program of telaprevir in 16 countries, for patients with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis. This interim analysis is of 16 week data from the 209 patients from Romania.

Methods
=======

Patients were treated with telaprevir in combination with peginterferon alfa and ribavirin (PR) for 12 weeks, followed by PR for 12 or 36 weeks. Severe fibrosis/cirrhosis was defined by liver biopsy (Metavir F3-4 or Ishak 3-6) or non-invasive tests. Platelet count \>90,000/cmm was required at entry. HCV RNA was evaluated at baseline and Weeks 4 and 12 of treatment. Virological response was defined as serum HCV RNA not detected, for the Intent to Treat (ITT) population.

Results
=======

Mean age was 52 years; 47% were male and 100% Caucasian, 59% had HCV RNA levels ≥800,000 IU/mL, 58%/42% had severe fibrosis/cirrhosis, 2% had genotype 1a, 14% were treatment naïve, 75% prior relapsers, 3% prior partial responders, 7% prior null responders and 1% had prior viral breakthrough. HCV RNA responses (percent undetectable) at weeks 4 and 12 (ITT analysis) are shown in Table [1](#T1){ref-type="table"}.

  Percent HCV RNA not detected    Week 4 (RVR)   Week 4+12 (eRVR)   Week 12
  ------------------------------- -------------- ------------------ ---------
  Treatment-naïve (n=30)          73%            70%                93%
  Prior relapser (n=156)          85%            81%                94%
  Prior partial responder (n=6)   100%           83%                83%
  Prior null responder (n=15)     80%            73%                80%
  Overall^a^ (n=209)              83%            79%                92%

^a^includes 2 patients with prior virological break-through, not in four categories above

Nine patients (4%) discontinued TVR due to adverse events, including six (3%) for rash and one (\<1%) for anaemia. The rate of serious adverse events was 9% and no patients died during the study.

Conclusion
==========

In this telaprevir early access program for hard-to-cure patients with severe fibrosis or compensated cirrhosis, early on-treatment virological responses are encouraging. Rates of discontinuation of telaprevir for adverse events were similar to Phase 3 trials.
